Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Jang, Jin Sung ^a   Lee, Adam ^b   Li, Jun ^a,c   Liyanage, Hema ^d   Yang, Yanan ^a   Guo, Lixia ^a   Asmann, Yan W ^a   Li, Peter W ^a   Erickson Johnson, Michele ^a   Sakai, Yuta ^a   Sun, ZhiFu ^a   Jeon, Hyo Sung ^e   Hwang, Hayoung ^f   Bungum, Aaron O ^a   Edell, Eric S ^a   Simon, Vernadette A ^a   Kopp, Karla J ^a   Eckloff, Bruce ^a   Oliveira, Andre M ^a   Wieben, Eric ^a   Aubry, Marie Christine ^a   Yi, Eunhee ^a   Wigle, Dennis ^a   Diasio, Robert B ^b   Yang, Ping ^a   Jen, Jin ^a   more..

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c JILIN UNIVERSITY   (China)

^d SEQUENOM INC   (United States)

^e Kyungpook National University School of Medicine   (South Korea)

^f Daegu Gyeongbuk Medical Innovation Foundation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR PROTEIN; ONCOPROTEIN; SND1 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; AGED; CANCER STAGING; FEMALE; GENE ORDER; GENETIC TRANSCRIPTION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; ONCOGENE; PATHOLOGY; PHOSPHORYLATION; REPRODUCIBILITY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE ORDER; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASM STAGING; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; ONCOGENES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION, GENETIC;

EID: 84929600898     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09755     Document Type: Article

References (33)

1. Wakelee, H. A. et al. Lung cancer incidence in never smokers. J Clin Oncol 25, 472-478 (2007).
2. Sun, S., Schiller, J. H. & Gazdar, A. F. Lung cancer in never smokers - a different disease. Nat Rev Cancer 7, 778-790 (2007).
3. Subramanian, J. & Govindan, R. Lung cancer in never smokers: a review. J Clin Oncol 25, 561-570 (2007).
4. Paik, P. K. et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29, 2046-2051 (2011).
5. Varghese, A. M. et al. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. J Thorac Oncol 8, 123-125 (2013).
6. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America 101, 13306-13311 (2004).
7. Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. The lancet oncology 12, 175-180 (2011).
8. Gazdar, A. F., Shigematsu, H., Herz, J. & Minna, J. D. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 10, 481-486 (2004).
9. Massarelli, E. et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer. Clin Cancer Res 13, 2890-2896 (2007).
10. Pao, W. et al. KRAS mutations and primary resistanceoflung adenocarcinomasto gefitinib or erlotinib. PLoS Med 2, e17 (2005).
11. Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer discovery 1, 44-53 (2011).
12. Boland, J. M. et al. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol 8, 574-581 (2013).
13. Forment, J. V., Kaidi, A. & Jackson, S. P. Chromothripsis and cancer: causes and consequences of chromosome shattering. Nat Rev Cancer 12, 663-670 (2012).
14. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
15. Marchetti, A. et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23, 857-865 (2005).
16. Ciampi, R. et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115, 94-101 (2005).
17. Cin, H. et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta neuropathologica 121, 763-774 (2011).
18. Hutchinson, K. E. et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 19, 6696-6702 (2013).
19. Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16, 793-798 (2010).
20. Lee, N. V. et al. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though MAPK activation. PloS one 7, e39653 (2012).
21. Tong, X., Drapkin, R., Yalamanchili, R., Mosialos, G. & Kieff, E. The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol 15, 4735-4744 (1995).
22. Kuruma, H. et al. Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. Am J Pathol 174, 2044-2050 (2009).
23. Santhekadur, P. K. et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. J Biol Chem 287, 13952-13958 (2012).
24. Yi, E. S. et al. Correlation of IHC and FISH for ALK gene rearrangement in nonsmall cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6, 459-465 (2011).
25. Asmann, Y. W. et al. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res 39, e100 (2011).
26. Asmann, Y. W. et al. Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer. Cancer research 72, 1921-1928 (2012).
27. Spurgeon, S. L., Jones, R. C. & Ramakrishnan, R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PloS one 3, e1662 (2008).
28. Erickson-Johnson, M. R. et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest 91, 1427-1433 (2011).
29. Drmanac, R. et al. Human genome sequencing using unchained base readson self-assembling DNA nanoarrays. Science 327, 78-81 (2010).
30. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297-1303 (2010).
31. Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods 8, 652-654 (2011).
32. Yang, Y. et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest 121, 1373-1385 (2011).
33. Sutherland, R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240, 177-184 (1988).